옵션 체인은 다양한 행사가격과 만기일에 대한 Liberty Media의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Liberty Media에 대한 시장 심리를 평가합니다..

Liberty Media (NASDAQ:FWONK) 주식, 옵션 체인

Liberty Media

Liberty Formula One Gr

Liberty Formula One Group

Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.

stock_whisper_index_logo_6_copy

Exclusives

Trading Ideas

$SUI

FWONA

FWONK

IONQ

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스프라우츠, 아이온큐, 닥터 페퍼, 선 커뮤니티즈 및 포뮬러 원

Los,Angeles,-,Dec,15:,Ryan,Reynolds,At,The,Ryan

Entertainment

IPOs

TMUS

배우 라이언 레이놀즈를 최고 크리에이티브 책임자(CCO)로 둔 한 마케팅 회사는 2025년 기업공개를 계획하고 있으며, 대형 스크린에서 &#39;데드풀&#39;을 연기한 것으로 가장 잘 알려진 이 배우의 최근 성공 사례를 추가할 예정이다.

라이언 레이놀즈의 10억 달러 행진, 그의 바이럴 마케팅 회사가 다음에 상장될 것인가?

Los,Angeles,-,Nov,03:,Ryan,Reynolds,Arrives,For,Netflixs

Education

Entrepreneurship

Success Stories

배우 라이언 레이놀즈는 요즘 극장가에서 데드풀(Deadpool) 역할로 가장 잘 알려져 있다. 이 역할은 현재 극장에서 상영 중인 세 번째 프랜차이즈 영화로 거대 미디어인 월트 디즈니 컴퍼니(NYSE:DIS)의 기록을 세우는 역할이다.

라이언 레이놀즈는 데드풀로 박스오피스를 장악하는 동시에 수십억 달러 규모의 사업을 구축

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Liberty Media Corp

WIIM

VLRS

Controladora Vuela shares are trading lower after the company reported worse-than-expected Q1 EPADS results.

Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock traded higher on Monday, with a session volume of 4.49 million compared to the average of 1.2 million, according to data from <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
On Monday, the company reported confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.
The data will be presented at the American Association for Cancer <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45034093/portage-biotech-reports-confirmatory-preclinical-results-in-mesothelioma-supporting-first-in-human" rel="noreferrer noopener">Research (AACR) Annual Meeting</a>.
The new data in a murine mesothelioma model demonstrated single-agent activity for PORT-7, which was superior to treatment with a single-agent anti-PD1 antibody.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42536777/whats-going-on-with-portage-biotech-shares-tuesday" rel="noreferrer noopener">What&#8217;s Going On With Portage Biotech Shares Tuesday</a>?
Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone.
Immunohistochemistry of the tumors revealed the formation of tertiary lymphoid structures in the mice receiving the combination.
This indication of a favorable immune response was accompanied by increases in immune effector cells in mice treated with the combination. Mesothelioma is an aggressive and rare type of cancer that affects the mesothelium, a thin layer of tissue lining internal organs like the lungs, abdomen, and heart.
Portage is making preparations to commence a first-in-human clinical trial with PORT-7.
In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor.
Portage plans to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial.
The company says this will mark the first time two highly selective A2A and A2B antagonists are combined in patients to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment.
Portage Biotech presented new preclinical data for PORT-7 (TT-4) at the 2025 European&nbsp;Lung <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44541972/why-is-portage-biotech-stock-skyrocketing-friday" rel="noreferrer noopener">Cancer Congress in March</a>.
The new data demonstrate both single-agent activity for PORT-7 and a dramatic &gt;90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44524033/portage-biotech-reports-promising-preclinical-results-in-mesothelioma-supporting-first-in-human-tr" rel="noreferrer noopener">mesothelioma animal model</a>.
Price Action: PRTG stock is up 42.3% at $12.03 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45020558/nikes-faces-china-challenges-and-tariff-pressures-says-analyst" target="_blank" rel="noreferrer noopener">China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst</a></li>
</ul>

Biotech

News

Health Care

Movers

General

PRTG

Portage Biotech Stock Surges As It Prepares For Human Trial

F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) will release earnings results for the second quarter, after the closing <a href="https://www.benzinga.com/quote/ffiv/earnings">bell on Monday, April 28</a>.
Analysts expect the Seattle, Washington-based company to report quarterly earnings at $3.11 per share, up from $2.91 per share in the year-ago period. F5 projects to report quarterly revenue at $719.68 million, compared to $681.35 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 17, F5 named Angelique Okeke as General Counsel.
F5 shares rose 0.7% to close at $270.03 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/FFIV/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Samik Chatterjee maintained a Neutral rating and cut the price target from $296 to $285 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Morgan Stanley analyst Meta Marshall maintained an Equal-Weight rating and slashed the price target from $310 to $269 on April 8, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Piper Sandler analyst James Fish maintained a Neutral rating and slashed the price target from $304 to $262 on April 8, 2025. This analyst has an accuracy rate of 64%.</li>
<li>B of A Securities analyst Tal Liani maintained an Underperform rating and raised the price target from $180 to $260 on Jan. 31, 2025. This analyst has an accuracy rate of 75%.</li>
<li>RBC Capital analyst Matthew Hedberg maintained a Sector Perform rating rating and increased the price target from $260 to $310 on Jan. 29, 2025. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying FFIV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28040714/image-185-1024x584.png" alt="" class="wp-image-890325" style="width:641px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28040714/image-185-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28040714/image-185-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28040714/image-185-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28040714/image-185.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

FFIV

F5 Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

POET

POET Technologies shares are trading higher after the company announced a $25 million offering of 5 million units at $5 per unit.

Bernstein analyst Douglas Harned upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Market Perform to Outperform and raises the price target from $181 to $218.

Upgrades

Bernstein Upgrades Boeing to Outperform, Raises Price Target to $218

Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported <a href="https://www.benzinga.com/pressreleases/25/04/g45034733/roper-technologies-announces-first-quarter-financial-results" target="_blank" rel="noreferrer noopener">first-quarter results</a> Monday, including quarterly adjusted earnings per share of $4.78, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the street view of</a> $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44460794/roper-technologies-announces-1-65-billion-centralreach-acquisition-targets-20-growth" rel="noreferrer noopener">Roper Technologies Announces $1.65 Billion CentralReach Acquisition, Targets 20%+ Growth</a>
Revenue increased by 12%, with an 8% contribution from acquisitions and a 5% increase in organic revenue.
The company exited the quarter with cash and equivalents worth $372.8 million and net inventories worth $125.5 million.
Roper Technologies&#8217; long-term debt (net of the current portion) as of quarter end was $6.46 billion, higher than $6.58 billion as of December 31, 2024.
CEO Neil Hunn said that, despite an uncertain macroeconomic backdrop, the company raised its full-year outlook, underpinned by demand for its mission-critical solutions and expansion of its recurring revenue base. Additionally, it is well-positioned to continue executing its capital deployment strategy, fueled by its significant M&amp;A firepower and a large pipeline of acquisition opportunities.
Outlook:&nbsp;Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00),&nbsp;versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
The company anticipates adjusted EPS of $4.80- $4.84 for the second quarter, compared to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the $4.86 estimate</a>.
Price Action: ROP stock is down 0.49% to $554.95 in the premarket at last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst" target="_blank" rel="noreferrer noopener">These Semiconductor Stocks To Face Least Tariffs Impact Compared To Intel</a></li>
</ul>
Photo: Shutterstock

Guidance

Roper Lifts 2025 Guidance After Solid Q1, CEO Sees Growth Ahead Despite Economic Uncertainty

Macro Economic Events

Econ #s

Economics

Dallas Fed Mfg Business Index For April -35.8 Vs -16.3 Prior

Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) has outperformed the market over the past 5 years by 9.62% on an annualized basis producing an average annual return of 23.88%. Currently, Equitable Holdings has a market capitalization of $15.58 billion. 
Buying $1000 In EQH: If an investor had bought $1000 of EQH stock 5 years ago, it would be worth $2,761.74 today based on a price of $50.63 for EQH at the time of writing.
<h3>Equitable Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745850615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/25/04/45038161/cemexs-q1-results-show-strong-emea-growth-offset-by-mexican-market-struggles">first-quarter results</a>.
The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion. Net sales fell 7% year over year (Y/Y), mainly due to lower volumes in Mexico. EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Cemex expects recurrent yearly EBITDA savings of at least $150 million in 2025 and $350 million by 2027.
Cemex shares jumped 4.2% to $6.16 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares jumped 39.4% to $1.13 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) surged 30% to $29.02 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 24.5% to $4.07.</li>
<li>Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) gained 20.3% to $2.6350 as the company entered into definitive agreement to sell its Hospitality Solutions business unit to TPG for $1.1 billion.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 17.4% to $8.23.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 15.9% to $3.5350.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) climbed 12.6% to $11.96.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) gained 12.2% to $47.83.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 12% to $24.49 as the company announced the FDA approval of its yield enhancement production process.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) gained 10% to $25.79.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) gained 10% to $10.85 after the company highlighted nearly four-year duration of response in OLYMPUS long-term follow-up study of JELMYTO.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) rose 7.6% to $7.41.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 6.1% to $29.82.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 5.4% to $6.63. Truist Securities analyst Youssef Squali upgraded Peloton Interactive from Hold to Buy.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

ADMA

CGON

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PLUG

PONY

PTON

RAPP

SABR

SMMT

URGN

VEON

WOLF

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday

Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares are trading higher premarket on Monday after the company disclosed that it has entered into an agreement with Oberland Capital Management LLC<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45035764/biohaven-announces-investment-up-to-600-million-by-oberland-capital" rel="noreferrer noopener"> to invest up to $600 million</a>.
The investment is structured through a non-dilutive Note Purchase Agreement (NPA). The first tranche of $250 million in gross proceeds is expected to be funded at closing on or before April 30, 2025.
Following FDA approval of troriluzole, Biohaven may draw an additional $150 million at its option, while another $200 million could be made available upon mutual agreement for strategic acquisitions and related expenses, subject to specific conditions.
Also Read: <a href="https://www.benzinga.com/25/03/44087186/strong-igg-reduction-data-positions-biohavens-bhv-1300-as-potential-autoimmune-therapy" target="_blank" rel="noreferrer noopener">Strong Immunoglobulin Reduction Data Positions Biohaven&#8217;s BHV-1300 As Potential Autoimmune Therapy</a>
The NPA also grants Oberland a right to regulatory milestone payments through 2030 and tiered single-digit royalties on global net sales of troriluzole for up to 10 years, capped at a predetermined multiple of the invested amount.
The additional funding is expected to bolster Biohaven's clinical trial programs across its development portfolio and support commercialization initiatives ahead of a potential U.S. FDA approval of troriluzole for spinocerebellar ataxia (SCA), a group of rare, progressively debilitating, and fatal genetic disorders currently lacking approved treatments.
As of Dec. 31, cash, cash equivalents, marketable securities and restricted <a href="https://www.benzinga.com/pressreleases/25/03/n44074016/biohaven-reports-recent-business-developments-and-fourth-quarter-and-full-year-2024-financial-resu" target="_blank" rel="noreferrer noopener">cash stood at around $489 million</a>.
Investors can gain exposure to the stock via Simplify Health Care ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINK#NYSE">PINK</a>) and iShares Trust iShares Neuroscience and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBRN#NYSE">IBRN</a>).
Price Action: Biohaven shares are up 5.85% at $21.00 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44401719" target="_blank" rel="noreferrer noopener">Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data</a></li>
</ul>

Equities

Mid Cap

Financing

BHVN

iShares Trust iShares Neuroscience and Healthcare ETF

IBRN

PINK

Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland

Sabre shares are trading higher after the company announced that TPG agreed to acquire Sabre's Hospitality Solutions business.

XRTX

XRTX stock has given up its prior gain. XORTX Therapeutics shares were trading higher after the comapny announced that the patent "Xanthine Oxidase Inhibitor Formulations" will be granted by the European Patent Office.

JMP Securities analyst David Scharf reiterates Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Bread Finl Hldgsto Market Perform

Wells Fargo analyst Joe Quatrochi maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and lowers the price target from $185 to $150.

Wells Fargo Maintains Overweight on ARM Holdings, Lowers Price Target to $150

Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced plans on Monday to <a href="https://www.benzinga.com/pressreleases/25/04/n45035022/marriott-international-to-acquire-the-citizenm-brand">buy the lifestyle hotel brand</a> CitizenM.
The acquisition is expected to help Marriott expand offerings for its guests and Marriott Bonvoy loyalty members across global markets. CitizenM has 36 hotels operating in over 20 cities worldwide, including in New York, London, Paris and Rome.
CitizenM also has three additional hotels under construction, slated for completion by mid-2026. Long-term expansion is planned across Marriott's global regions.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800444/goldman-sachs-cuts-outlook-for-these-hotel-and-lodging-stocks-as-potential-recession-looms">Goldman Sachs Cuts Outlook For These Hotel And Lodging Stocks As Potential Recession Looms</a>
Under the terms of the deal, Marriott will pay $355 million for CitizenM and its related intellectual property. The CitizenM properties currently owned and leased by the seller will shift to new long-term franchise agreements managed by Marriott.
&#8220;As we continue to drive best-in-class experiences for travelers, today&#8217;s announcement builds upon Marriott&#8217;s commitment to enhance options for guests and Marriott Bonvoy members,&#8221; said&nbsp;Marriott president and CEO, Anthony Capuano.
&#8220;Marriott has a proven track record of growing acquired brands significantly by leveraging our global development ecosystem, the benefits of our industry-leading affiliation cost structure, and the power of our award-winning Marriott Bonvoy loyalty platform.&#8221;
Marriott <a href="https://www.benzinga.com/news/earnings/25/02/43629316/marriott-tops-q4-estimates-as-2025-outlook-pressures-stock">held $400 million in cash and equivalents</a> as of Dec. 31, 2024.
Future growth incentives could see the seller earn up to an additional $110 million, based on brand expansion achievements over a multi-year timeframe, starting in the fourth year after closing. 
CitizenM, established in 2008, is known for its tech-driven hospitality, artistic design, and smart use of space, offering travelers modern rooms, and rooftop terraces at an affordable price.
Pending regulatory approvals, the acquisition is expected to close in 2025. Marriott projects that this move will help drive its net room growth to nearly 5% for the full year 2025.
Price Action: MAR shares traded higher by 1.75% at $240.34 at last check Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011035/meta-booz-allen-launch-space-llama-ai-system-for-space-station-operations">Meta, Booz Allen Launch &#8216;Space Llama&#8217; AI System For Space Station Operations</a></li>
</ul>
Image: Shutterstock

Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers

Wells Fargo analyst Steven Cahall maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Overweight and lowers the price target from $129 to $93.

ROKU

Wells Fargo Maintains Overweight on Roku, Lowers Price Target to $93

JMP Securities analyst Constantine Davides reiterates Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from Market Perform to Market Perform.

JMP Securities Reiterates Market Perform on Agilon Healthto Market Perform

Wells Fargo analyst Steven Cahall maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Equal-Weight and raises the price target from $380 to $400.

CHTR

Wells Fargo Maintains Equal-Weight on Charter Communications, Raises Price Target to $400

Wells Fargo analyst Christian Wetherbee maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Equal-Weight and lowers the price target from $400 to $260.

SAIA

Wells Fargo Maintains Equal-Weight on Saia, Lowers Price Target to $260

Wells Fargo analyst Matthew Akers maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Overweight and raises the price target from $438 to $513.

CACI

Wells Fargo Maintains Overweight on CACI International, Raises Price Target to $513

Press Releases

Liberty Media Corporation Announces Plan to Split Off Liberty Live Group

Greg Maffei to Step Down as Liberty Media CEO at Year-End in Conjunction with Transactions to Simplify Corporate Structure

Liberty Media Appoints Chase Carey to Board of Directors

Liberty Media Names Robert R. Bennett as Vice Chairman of Board of Directors

Liberty Media Statement on European Commission Decision to Open Phase II Investigation of Proposed Acquisition of MotoGP™

Liberty Media Names Derek Chang as President & Chief Executive Officer

Liberty Media Corporation Announces Fourth Quarter Earnings Release and Conference Call

Liberty Media Corporation Announces 2025 Virtual Annual Meeting of Stockholders

Liberty Media Corporation Reports Fourth Quarter and Year End 2024 Financial Results

Liberty Media Corporation Announces First Quarter Earnings Release and Conference Call

LLYVA

LLYVK

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series A

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lions Gate Entertainment Corporation Class A Voting Shares

Lions Gate Entertainment Corporation Class B Non-Voting Shares

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Liberty Media

Liberty Media (FWONK) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌